Organization (Industry)
Vistagen Therapeutics, Inc.
ClinicalTrials.gov lists Vistagen Therapeutics, Inc. as lead sponsor of 11 trials. It has 8 active development programs and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Vistagen Therapeutics, Inc.: 11 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (9)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Anxiety Disorders | 6 |
| Phobia, Social | 6 |
| Drug-Related Side Effects and Adverse Reactions | 1 |
| Dyskinesia, Drug-Induced | 1 |
| Major Depressive Disorder | 1 |
Showing 5 of 9 disease areas.
Trials by start year as sponsor or collaborator (6)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 2 |
| 2022 | 1 |
| 2021 | 5 |
| 2018 | 2 |
| 2011 | 1 |
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (8)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Fasedienol Nasal Spray | Phobia, Social | Phase 3 | 2 |
| Fasedienol Nasal Spray | Anxiety Disorders | Phase 3 | 2 |
| PH94B Nasal Spray | Phobia, Social | Phase 3 | 2 |
| PH94B Nasal Spray | Anxiety Disorders | Phase 3 | 2 |
| PH94B | Anxiety Disorders | Phase 3 | 1 |
Showing 5 of 8 active programs.
Approved assets (1)
| Drug | Trials |
|---|---|
| Probenecid | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 86% hit target (n=7) | 14% on time (n=7) |
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Molecular pharmaceutics | 1 |
| Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology | 1 |
| Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) | 1 |
| Scandinavian journal of pain | 1 |
| The American journal of psychiatry | 1 |
SEC-reported annual financials (12)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2026 | not reported | -69,685,000 | 54,974,000 |
| 2025 | not reported | -51,418,000 | 39,375,000 |
| 2024 | not reported | -29,362,000 | 20,022,000 |
| 2023 | -227,000 | -59,248,000 | 44,377,000 |
| 2022 | 1,109,000 | -47,762,400 | 35,407,800 |
| 2021 | 1,089,500 | -17,934,200 | 11,925,700 |
| 2020 | 0 | -20,774,000 | 13,374,200 |
| 2019 | not reported | -24,589,600 | 17,098,500 |
| 2018 | 0 | -14,345,900 | 7,762,500 |
| 2017 | 1,250,000 | -10,255,500 | 5,203,700 |
Showing 10 of 12 fiscal years.
Financing and grant events (31)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-06-17 | Other financing | not disclosed | Edgar offerings |
| 2025-06-17 | ATM offering | 3,443,612 | Sec extracted |
| 2023-11-02 | Royalty / licensing | 1,500,000 | Sec extracted |
| 2023-10-03 | Other financing | not disclosed | Edgar offerings |
| 2023-10-02 | Public offering | 93,500,000 | Sec extracted |
Showing 5 of 31 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2026 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2026 | not disclosed | not disclosed |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 1 |
| Parexel | Uses vendor | 1 |
| Cato Research | Co sponsors trial with | 1 |
Latest dated events (44)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026 H1 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2025-06-17 | At-the-market offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-06-17 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-01-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-09-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 44 events.
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| F2 | Trial sponsor | Named in trial exclusion criteria |
| F3 | Trial sponsor | Named in trial exclusion criteria |
| F2 | Trial sponsor | Mentioned in trial text |
| F3 | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.